About the Company
avidity biosciences is pioneering a new class of precision medicines – antibody-sirna conjugates (asc™) – to deliver nucleic acid therapeutics against genetic drivers of disease. our ascs have drug-like properties similar to antibodies and antibody-drug conjugates. importantly, their unique sirna-based “payloads” permit selective targeting of disease-associated mrnas against virtually any target of interest. our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. we strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. we have also attracted support from top-tier investors including f-prime capital, ecor1 capital, brace pharma and other sophisticated
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RNA News
Which Is a Better Investment, Apellis Pharmaceuticals Inc or Avidity Biosciences Inc Stock?
Learn more about whether Apellis Pharmaceuticals Inc or Avidity Biosciences Inc is a better investment based on AAII's A+ ...
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Cantor Fitzgerald has initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA), noting the company has the complete package ...
A Closer Look at 5 Analyst Recommendations For Avidity Biosciences
In the assessment of 12-month price targets, analysts unveil insights for Avidity Biosciences, presenting an average target ...
Avidity Biosciences Inc
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design ...
Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)
Michael Maclean, Chief Financial Officer of Avidity Biosciences Inc (NASDAQ:RNA), sold 40,000 shares of the company on March 13, 2024, according to a recent SEC filing. The transaction was ...
Avidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular Disease
Avidity Biosciences Inc (NASDAQ:RNA) revealed new long-term AOC 1001 data from the MARINA open-label extension (MARINA-OLE) ...
Avidity Biosciences CFO sells shares worth nearly $1m
In a recent transaction, Michael F. MacLean, the Chief Financial Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), sold 40,000 shares of the company's common stock. The sale, which took place on ...
Loading the latest forecasts...